THIS DOCUMENT IS A CONFIRMING ELECTRONIC COPY OF
THE FORM 8-K FILED IN PAPER ON JANUARY 4, 1996.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 28, 1995
ONCOR, INC.
(Exact name of registrant as specified in its charter)
Maryland 0-16177 52-1310084
(State or other jurisdiction (Commission (IRS Employer
of incorporation) file number) Identification No.)
209 Perry Parkway, Gaithersburg, Maryland 20877
(Address of principal executive offices) (Zip Code)
(301) 963-3500
(Registrant's telephone number, including area code)
N.A.
(Former name or former address, if changed since last report)
Item 5. Other Events
See attached press release.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
ONCOR, INC.
(Registrant)
By: /s/ Stephen Turner
Name: Stephen Turner
Title: Chief Executive Officer
Dated: December 29, 1995
PRESS RELEASE
For Further Information Contact: Oncor, Inc.
209 Perry Parkway
Stephen Turner Gaithersburg, MD 20877
John Coker (301)963-3500
Fax (301)926-6129
E-mail: [email protected]
FOR IMMEDIATE RELEASE
ONCOR, INC. COMPLETES $10 MILLION PRIVATE PLACEMENT
Gaithersburg, Maryland -- December 28, 1995 . . . Oncor, Inc.
(AMEX: ONC) today announced conclusion of a private placement
with institutional investors totaling $10 million consisting of
768,384 shares of common stock for $3.0 million, and $7.0 million
of 4.5% three-year unsecured notes convertible into shares of
common stock of the company. The private placement was made
pursuant to Regulation D of the Securities Act of 1933.
Oncor will be filing a registration statement covering resale of
the common stock issued today and issuable upon conversion of the
notes. The notes become convertible in three equal tranches 15,
35 and 65 days after effectiveness of the registration statement.
They are convertible at a price equal to 80.5% of the market
value of the common stock at the time of conversion.
"This private placement enhances the company's financial strength
for pursuit of our long-term objectives," said Stephen Turner,
Oncor's Chairman and Chief Executive Officer. "The structure
of the financing is such that future issuances of the common
stock from the financing will be based upon future market prices
for Oncor's stock." With the closing, the company has
approximately $16 million in cash and cash equivalents.
Oncor, Inc. develops, manufactures and markets gene-based test
systems and related products for use in the detection and
management of cancer and other human disease.
# # #
